SCHEMBL7649170

SCHEMBL7649170

Cc1cc(C(C)(C)C)c(C(O)c2ccccn2)c(C(C)(C)C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 7/20 0.42
CYP3A4 P08684 2/20 0.40
PDE10A Q9Y233 2/20 0.40
MAPT P10636 2/20 0.38
BRD4 O60885 1/20 0.38
ALDH1A1 P00352 2/20 0.38
CA2 P00918 1/20 0.38
POLB P06746 1/20 0.38
TYR P14679 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP2C19 P33261 1/20 0.35
RECQL P46063 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3346780 0.76 BRD4 (0.51) CYP3A4PDE10AMAPTBRD4ALDH1A1
SCHEMBL8015316 0.75 IDH1 (0.48) IDH1CYP3A4MAPTALDH1A1CA2
SCHEMBL3048607 0.72 MAPT (0.55) CYP3A4MAPTALDH1A1POLBKDM4E
SCHEMBL29864658 0.72 MAPT (0.55) CYP3A4MAPTALDH1A1POLBKDM4E
SCHEMBL10704920 0.71 IDH1 (0.45) IDH1CYP3A4MAPTBRD4ALDH1A1
SCHEMBL23610040 0.70 BRD4 (0.49) CYP3A4MAPTBRD4ALDH1A1KDM4E
SCHEMBL14081505 0.70 BRD4 (0.49) CYP3A4MAPTBRD4ALDH1A1KDM4E
SCHEMBL29485027 0.70 BRD4 (0.49) CYP3A4MAPTBRD4ALDH1A1KDM4E
SCHEMBL28799220 0.70 MAPT (0.53) CYP3A4MAPTBRD4ALDH1A1POLB
Hydrochloric Acid SCHEMBL10324019 0.70 MAPT (0.53) CYP3A4MAPTBRD4ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020065315-A1 Ion channel modulating agents POSEIDON PHARMACEUTICALS A/S (DK) 2002-05-30 US claimed
EP-1178963-A1 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2002-02-13 EP claimed
WO-2000069823-A1 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2000-11-23 WO claimed
US-20020065315-A1 Ion channel modulating agents POSEIDON PHARMACEUTICALS A/S (DK) 2002-05-30 US disclosed
EP-1178963-A1 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2002-02-13 EP disclosed
WO-2000069823-A1 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065315-A1 Ion channel modulating agents KCNN1, KCNN3, KCNN2 IDH1 2973/4885CYP3A4 3142/4885PDE10A 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.